Jump to content

Alexander Shulgin Research Institute

Add links
From Wikipedia, the free encyclopedia
Alexander Shulgin Research Institute
IndustryPharmaceutical; Psychedelic medicine
Founded2021; 4 years ago (2021)
FounderAnn Shulgin; Paul Daley; Nicholas Cozzi
Websiteshulginresearch.net

Alexander Shulgin Research Institute (ASRI) is an organization developing novel psychedelic and entactogen drugs as potential pharmaceuticals, among other activities.[1][2][3][4][5] Its goal is to advance the scientific work and legacy of psychedelic chemist Alexander "Sasha" Shulgin and to complete his unfinished projects.[3][4][5]

The ASRI was informally established by Alexander Shulgin in the 1980s.[1] However, discussions to formally establish the institute began shortly after Shulgin's passing in 2014.[6] The organization was formally incorporated on April 19th, 2021, Bicycle Day, by Ann Shulgin, the late widow of Alexander Shulgin, and by psychedelic chemists and longtime Shulgin research colleagues Paul Daley and Nicholas Cozzi.[1][2][4] Cozzi was the organization's first president between 2020 and 2025.[2] He was succeeded by Daley in March 2025.[citation needed] As of April 2025, ASRI has filed and/or been granted several patents covering various entactogenic and psychedelic compounds.[7][8][9][10][11] Shulgin himself was not averse to intellectual property (IP) protection and held patents for drugs such as DOM, DOET, Ariadne and methylone.[1][12][13]

Pharmaceutical candidates under development at ASRI include ASR-3001 (5-MeO-iPALT; a "second-generation, fast-acting tryptamine" said to produce an internal psychedelic state without sensory disturbances) and ASR-2001 (2CB-5PrO; a phenethylamine-based non-hallucinogenic serotonin 5-HT2A receptor agonist).[1][2][14][15][7][8] XOB, a drug invented by Cozzi, is a dual-action serotonin 5-HT2A receptor antagonist and voltage-gated sodium channel blocker.[16] ASRI has more than 500 compounds in its collection, many of which were originally developed by Alexander Shulgin.[1]

A related initiative is the Alexander Shulgin Archiving Project (or The Shulgin Archive), which is a co-project with Erowid that began by 2007.[6][12] An earlier group preceding the ASRI was "Team Shulgin", which was formed by 2010 and comprised Alexander and Ann Shulgin, Ann Shulgin's daughter Wendy Tucker (the editor of PiHKAL and TiHKAL and the head of Transform Press), Paul Daley, Tania Manning, and Greg Manning.[17][18]

Selected publications

[edit]
  • Denomme N, Hernandez CC, Bock HA, Ohana RF, Bakshi S, Sherwood AM, McCorvy JD, Daley PF, Callaway WB, Hull JM, Alt A, Isom LL, Cozzi NV (July 2024). "N-(4-Bromo-2,5-Dimethoxyphenethyl)-6-(4-Phenylbutoxy)Hexan-1-Amine (XOB): A Novel Phenylalkylamine Antagonist of Serotonin 2A Receptors and Voltage-Gated Sodium Channels" (PDF). Mol Pharmacol. 106 (2): 92–106. doi:10.1124/molpharm.123.000837. PMID 38821630.
  • Trout K, Daley PF (December 2024). "The origin of 2,5-dimethoxy-4-methylamphetamine (DOM, STP)" (PDF). Drug Test Anal. 16 (12): 1496–1508. doi:10.1002/dta.3667. PMID 38419183.

See also

[edit]

References

[edit]
  1. ^ a b c d e f Busby, Mattha (2 November 2023). "The Heirs to a Vault of Novel Psychedelics Take a Trip Into the Unknown". DoubleBlind Mag. Retrieved 27 February 2025.
  2. ^ a b c d Goldstein, Lara (10 July 2023). "Pioneering Psychedelics Scientist Alexander "Sasha" Shulgin's Legacy Lives On Via New Compounds And Research". Benzinga. Retrieved 27 February 2025.
  3. ^ a b Goldstein, Lara (11 July 2023). "A Chapter In Psychedelics History: Alexander Shulgin's 'Blending' Of Sensory Experiences With Science And Chemistry". Benzinga. Retrieved 27 February 2025.
  4. ^ a b c Goldstein, Lara (12 July 2023). "Discover ASRI: Exploring Alexander Shulgin's Scientific Legacy With Over 500 Psychedelic Compounds". Benzinga. Retrieved 27 February 2025.
  5. ^ a b Bauer, Barbara E. (31 December 2018). "Alexander Shulgin Research Institute". Psychedelic Science Review. Retrieved 28 February 2025.
  6. ^ a b Erowid (April 2015). "Shulgin Archiving Project with a Dispatch from the Shulgin Farm..." Erowid Extracts. Erowid. pp. 18–19. I first started paying regular visits to the Farm in order to play Go with Sasha. A few years ago, I began helping Team Shulgin with publishing and lending my entrepreneurial skills towards establishing the Alexander Shulgin Research Institute (ASRI). I've passed many hours at the Farm working on this Archiving Project.
  7. ^ a b WO patent 2024243599A1, Mark J. Martini; Nicholas V. Cozzi & Paul F. Daley et al., "Asymmetric phenylalkylamines", published 28 November 2024, assigned to Alexander Shulgin Research Institute 
  8. ^ a b WO patent 2023034645A2, Paul Daley; Nicholas Cozzi & Wyeth Baillie Callaway, "Asymmetric allyl tryptamines", published 9 March 2023, assigned to Alexander Shulgin Research Institute 
  9. ^ "Deuterated empathogens". Google Patents. 23 August 2022. Retrieved 25 April 2025.
  10. ^ "Fluorinated empathogens". Google Patents. 23 August 2022. Retrieved 25 April 2025.
  11. ^ "Use of deuterated empathogens as therapeutic agents". Google Patents. 14 June 2024. Retrieved 25 April 2025.
  12. ^ a b Trout K, Daley PF (December 2024). "The origin of 2,5-dimethoxy-4-methylamphetamine (DOM, STP)". Drug Test Anal. 16 (12): 1496–1508. doi:10.1002/dta.3667. PMID 38419183. New information has appeared in public revelations by Nick Sand and Tim Scully, and additional documentation emerged during the digitization process for the Alexander Shulgin Archiving Project, October 2015 through July 2022.
  13. ^ WO 9639133, Jacob III P, Shulgin AT, "Novel N-Substituted-2-Amino-3',4'-Methylene-dioxypropiophenones", published 1996-12-12, assigned to Neurobiological Technologies Inc. 
  14. ^ "Alexander Shulgin Research Institute discovers new phenylalkylamine compounds". BioWorld. 19 December 2024. Retrieved 27 February 2025.
  15. ^ "Delving into the Latest Updates on Alexander Shulgin Research Institute, Inc. with Synapse". Synapse. 23 January 2025. Retrieved 27 February 2025.
  16. ^ Denomme N, Hernandez CC, Bock HA, Ohana RF, Bakshi S, Sherwood AM, McCorvy JD, Daley PF, Callaway WB, Hull JM, Alt A, Isom LL, Cozzi NV (July 2024). "N-(4-Bromo-2,5-Dimethoxyphenethyl)-6-(4-Phenylbutoxy)Hexan-1-Amine (XOB): A Novel Phenylalkylamine Antagonist of Serotonin 2A Receptors and Voltage-Gated Sodium Channels" (PDF). Mol Pharmacol. 106 (2): 92–106. doi:10.1124/molpharm.123.000837. PMID 38821630.
  17. ^ "A Glimpse of the World after the War on Drugs". openDemocracy. 4 October 2011. Retrieved 28 February 2025. Team Shulgin (Sasha & Ann Shulgin, Paul Daley, Tania Manning) The Shulgin Index and Shulgin Legacy Project.
  18. ^ "'Born Illegal' -- Exploring the Powerful Advanced Psychedelics Invented by the Father of Ecstasy". 1 October 2010. Retrieved 28 February 2025. Paul Daley is part of a core group of people referred to as Team Shulgin by their friends, who help Ann and Sasha to carry on the legacy of their work. Team Shulgin includes Ann's daughter Wendy Tucker, who edited PIHKAL and the sequel,TIHKAL (Tryptamines I Have Known And Loved), and is the head of Transform Press, the publisher of Shulgin books; and Greg and Tania Manning, the Shulgin researchers/writers/archivists/personal assistants who live, work and travel with them.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Alexander_Shulgin_Research_Institute&oldid=1287259811"